Article
Rapamycin as an Adjunctive Therapy for NLRC4 Associated Macrophage Activation Syndrome
24 Sept 2018
Abstract excerpt
Gain of function (GOF) mutations affecting the inflammasome component NLRC4 are known to cause early-onset macrophage activation syndrome (MAS) and neonatal enterocolitis. Here we report a patient with a NLRC4 GOF mutation presenting with neonatal MAS efficiently treated with a combination of anakinra and rapamycin. Through in vitro studies, we show that rapamycin reduces both IL-1β and IL-18 secretion by the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
